[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @d_stock07734 d_stock d_stock posts on X about $nwbo, take the, $40b, investment the most. They currently have XXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::1660707117722902539/interactions)  - X Week XXXXXX +8.40% - X Month XXXXXX +44% - X Months XXXXXXX +230% - X Year XXXXXXX +91% ### Mentions: XX [#](/creator/twitter::1660707117722902539/posts_active)  - X Week XX -XX% - X Month XX +31% - X Months XXX +226% - X Year XXX +131% ### Followers: XXX [#](/creator/twitter::1660707117722902539/followers)  - X Week XXX +0.35% - X Month XXX +2.10% - X Months XXX +8.80% - X Year XXX -XX% ### CreatorRank: XXXXXXX [#](/creator/twitter::1660707117722902539/influencer_rank)  ### Social Influence [#](/creator/twitter::1660707117722902539/influence) --- **Social category influence** [stocks](/list/stocks) XXXX% [finance](/list/finance) XXXX% **Social topic influence** [$nwbo](/topic/$nwbo) #1, [take the](/topic/take-the) 0.49%, [$40b](/topic/$40b) 0.49%, [investment](/topic/investment) 0.49%, [long term](/topic/long-term) 0.49%, [drivers](/topic/drivers) 0.49%, [over the](/topic/over-the) 0.49%, [blockbuster](/topic/blockbuster) 0.49%, [$rvmd](/topic/$rvmd) 0.49%, [cest](/topic/cest) XXXX% **Top accounts mentioned or mentioned by** [@andrewcaravello](/creator/undefined) [@dcvaxdefender](/creator/undefined) [@alphavestcap](/creator/undefined) [@mdendream](/creator/undefined) [@maveric92283613](/creator/undefined) [@macdoji](/creator/undefined) [@flemmingbruce](/creator/undefined) [@dcvaxcohenm](/creator/undefined) [@rbioceutics](/creator/undefined) [@jascanlan](/creator/undefined) [@hoffmann6383](/creator/undefined) [@exosome](/creator/undefined) [@mazzulolorie](/creator/undefined) [@justinkeister5](/creator/undefined) [@richfairgrieve](/creator/undefined) [@aponiaanalytics](/creator/undefined) [@atlnsider](/creator/undefined) [@jackisb36178846](/creator/undefined) [@johnlane45](/creator/undefined) [@joeretired41](/creator/undefined) **Top assets mentioned** [Revolution Medicines, Inc. Common Stock (RVMD)](/topic/$rvmd) ### Top Social Posts [#](/creator/twitter::1660707117722902539/posts) --- Top posts by engagements in the last XX hours "@mazzulo_lorie @andrewcaravello Why would he leave for Regeneron as an associate director on field medical affairs Why did Roger Perlmutter take the CEO job of a startup one week after stepping down from Merck Did Merck place most of its $40b strategic investment after Perlmutter left" [X Link](https://x.com/d_stock07734/status/1978582037888909552) [@d_stock07734](/creator/x/d_stock07734) 2025-10-15T22:01Z XXX followers, XXX engagements "@bullishbruk Do you know what is TLR4 TLR4 can boost the production of TNFa and IL-12 p70 to strengthen anti-tumor immune response. $NWBO 10Q mentioned about TLR agonist. Most likely it could be TLR4. Now do your homework and find out which company owns TLR4" [X Link](https://x.com/d_stock07734/status/1978619931530031316) [@d_stock07734](/creator/x/d_stock07734) 2025-10-16T00:32Z XXX followers, XXX engagements "@mazzulo_lorie @andrewcaravello BPs would not take hectic working hours to complete the manufacturing facilities if they were not something concerning their future. Merck never chose the same type of hectic working hours to solve BCG shortage issue" [X Link](https://x.com/d_stock07734/status/1978689642711969973) [@d_stock07734](/creator/x/d_stock07734) 2025-10-16T05:09Z XXX followers, XXX engagements "@mazzulo_lorie @andrewcaravello Did you see how Merck set up and acquired Immune Design I was wondering if Merck was trying to do the same on $NWBO. But Merck didn't make it" [X Link](https://x.com/d_stock07734/status/1978690142643560870) [@d_stock07734](/creator/x/d_stock07734) 2025-10-16T05:11Z XXX followers, XXX engagements "$NWBO Going through the products from some BPs and wondering if those products can be combined with DCVax to treat cancer is really a wonderful experience. ACTIMMUNE (interferon gamma-1b): No need to explain this one. Aimovig (erenumab-aooe) is a CGRP inhiibtor: The inhibition of CGRP may lead to an increase in the DC's antigen-presenting capacity potentially boosting T-cell activation. By blocking CGRP's suppressive effects CGRP inhibitors can allow for greater DC activation and higher production of pro-inflammatory cytokines like TNF- which CGRP normally represses. Blocking CGRP's influence" [X Link](https://x.com/d_stock07734/status/1978845732179251457) [@d_stock07734](/creator/x/d_stock07734) 2025-10-16T15:29Z XXX followers, 3231 engagements "$NWBO It's interesting that Roche sponsored a trial on using the combination of XCR1 with DC vaccine and Atezolizumab (PD-L1 inhibitor) to treat late stage small cell lung cancer. Among XX patients enrolled XX% are PD-L1 negative. The results were presented one year ago. There will be a presentation on this trial next week. Long term survivors from Phase Ib-II trial of tumor-loaded monocyte-derived dendritic cell vaccination plus atezolizumab in ES-SCLC Not sure if the research institution at Spain is involved in the symphony. But it's good to see Roche has interest in DC vaccine therapy." [X Link](https://x.com/d_stock07734/status/1978925646622458197) [@d_stock07734](/creator/x/d_stock07734) 2025-10-16T20:46Z XXX followers, 3692 engagements "@Michael48826289 If I am not mistaken TIGIT inhibitor is among XX new growth drivers that Merck repeatedly claim to have blockbuster potentials" [X Link](https://x.com/d_stock07734/status/1978927292869943332) [@d_stock07734](/creator/x/d_stock07734) 2025-10-16T20:53Z XXX followers, XXX engagements "$NWBO $RVMD is going to face competition from Incyte. INCB161734 (KRAS G12D) Preliminary Phase X Results Of INCB161734 A Novel Oral KRAS G12D Inhibitor In Patients With Advanced Or Metastatic Solid Tumors (Session Title: Proffered paper session: Developmental therapeutics. October XX 8:45 10:20 a.m. ET 2:45 4:20 p.m. CEST. Abstract #916O.)" [X Link](https://x.com/d_stock07734/status/1979292412758626542) [@d_stock07734](/creator/x/d_stock07734) 2025-10-17T21:04Z XXX followers, 2089 engagements "$NWBO It seems like Merck is going to file the approval of oral PCSK9 inhibitor (MK-0616) as the treatment for hypercholesterolemia. No doubt Merck knows that MK-0616 can be used for cancer treatment and it is among XX new growth drivers that have blockbuster potential. DoD (W81XWH-21-1-0532) once sponsored a trial on using Amgen's PCSK9 inhibitor (Evolocumab) in combination with BMS's two checking point inhibitors to treat lung cancer. Dr. Scott Antonia was the PI of the trial. Regeneron also sponsored a trial similar to the above one and the combination adopted in the trial is Regneron's" [X Link](https://x.com/d_stock07734/status/1976146499659518445) [@d_stock07734](/creator/x/d_stock07734) 2025-10-09T04:43Z XXX followers, XXX engagements "You guys still think about BO. Merck acquired Verona and Prometheus. The presentations can provide the hints on how Merck prices a BO target. Can Merck do the same for NWBO Take a closer look at the lead candidates from the two companies to see if they can be something complementary to or synergistic with DCVax. Ohtuvayre a dual PDE3 and PDE4 inhibitor from Verona can be used to overcome immunosuppression due to tumor-associated neutrophils. When DCs loaded with tumor-associated peptides migrate to lymph nodes they want to contact t-cells as many as possible. That's why IL-2 from Prometheus" [X Link](https://x.com/d_stock07734/status/1976877785571320095) [@d_stock07734](/creator/x/d_stock07734) 2025-10-11T05:09Z XXX followers, XXX engagements "A collaboration trial between Merck and TILT Biotherapeutics on ovarian cancer. One of the conclusions is that Median progression-free survival and overall survival were XX and XXX days respectively. Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a and 2) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. (PROTA) The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial" [X Link](https://x.com/d_stock07734/status/1977604460680532234) [@d_stock07734](/creator/x/d_stock07734) 2025-10-13T05:17Z XXX followers, XXX engagements "$NWBO ESMO 2025 preview Merck hopes for Daiichi redemption Did Merck strike the deal with Daiichi after Merck replaced BMS as the sponsor for the SPORE project Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition Conclusions This study reveals that timing may impact how ATL-DC and aPD1 combined therapies can alter the immune landscape of GBM and highlights tumor-associated macrophages as a major obstacle to clinical benefit" [X Link](https://x.com/d_stock07734/status/1979294597751722147) [@d_stock07734](/creator/x/d_stock07734) 2025-10-17T21:13Z XXX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@d_stock07734 d_stock
d_stock posts on X about $nwbo, take the, $40b, investment the most. They currently have XXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXXX +8.40%
- X Month XXXXXX +44%
- X Months XXXXXXX +230%
- X Year XXXXXXX +91%
Mentions: XX #
- X Week XX -XX%
- X Month XX +31%
- X Months XXX +226%
- X Year XXX +131%
Followers: XXX #
- X Week XXX +0.35%
- X Month XXX +2.10%
- X Months XXX +8.80%
- X Year XXX -XX%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence stocks XXXX% finance XXXX%
Social topic influence $nwbo #1, take the 0.49%, $40b 0.49%, investment 0.49%, long term 0.49%, drivers 0.49%, over the 0.49%, blockbuster 0.49%, $rvmd 0.49%, cest XXXX%
Top accounts mentioned or mentioned by @andrewcaravello @dcvaxdefender @alphavestcap @mdendream @maveric92283613 @macdoji @flemmingbruce @dcvaxcohenm @rbioceutics @jascanlan @hoffmann6383 @exosome @mazzulolorie @justinkeister5 @richfairgrieve @aponiaanalytics @atlnsider @jackisb36178846 @johnlane45 @joeretired41
Top assets mentioned Revolution Medicines, Inc. Common Stock (RVMD)
Top Social Posts #
Top posts by engagements in the last XX hours
"@mazzulo_lorie @andrewcaravello Why would he leave for Regeneron as an associate director on field medical affairs Why did Roger Perlmutter take the CEO job of a startup one week after stepping down from Merck Did Merck place most of its $40b strategic investment after Perlmutter left"
X Link @d_stock07734 2025-10-15T22:01Z XXX followers, XXX engagements
"@bullishbruk Do you know what is TLR4 TLR4 can boost the production of TNFa and IL-12 p70 to strengthen anti-tumor immune response. $NWBO 10Q mentioned about TLR agonist. Most likely it could be TLR4. Now do your homework and find out which company owns TLR4"
X Link @d_stock07734 2025-10-16T00:32Z XXX followers, XXX engagements
"@mazzulo_lorie @andrewcaravello BPs would not take hectic working hours to complete the manufacturing facilities if they were not something concerning their future. Merck never chose the same type of hectic working hours to solve BCG shortage issue"
X Link @d_stock07734 2025-10-16T05:09Z XXX followers, XXX engagements
"@mazzulo_lorie @andrewcaravello Did you see how Merck set up and acquired Immune Design I was wondering if Merck was trying to do the same on $NWBO. But Merck didn't make it"
X Link @d_stock07734 2025-10-16T05:11Z XXX followers, XXX engagements
"$NWBO Going through the products from some BPs and wondering if those products can be combined with DCVax to treat cancer is really a wonderful experience. ACTIMMUNE (interferon gamma-1b): No need to explain this one. Aimovig (erenumab-aooe) is a CGRP inhiibtor: The inhibition of CGRP may lead to an increase in the DC's antigen-presenting capacity potentially boosting T-cell activation. By blocking CGRP's suppressive effects CGRP inhibitors can allow for greater DC activation and higher production of pro-inflammatory cytokines like TNF- which CGRP normally represses. Blocking CGRP's influence"
X Link @d_stock07734 2025-10-16T15:29Z XXX followers, 3231 engagements
"$NWBO It's interesting that Roche sponsored a trial on using the combination of XCR1 with DC vaccine and Atezolizumab (PD-L1 inhibitor) to treat late stage small cell lung cancer. Among XX patients enrolled XX% are PD-L1 negative. The results were presented one year ago. There will be a presentation on this trial next week. Long term survivors from Phase Ib-II trial of tumor-loaded monocyte-derived dendritic cell vaccination plus atezolizumab in ES-SCLC Not sure if the research institution at Spain is involved in the symphony. But it's good to see Roche has interest in DC vaccine therapy."
X Link @d_stock07734 2025-10-16T20:46Z XXX followers, 3692 engagements
"@Michael48826289 If I am not mistaken TIGIT inhibitor is among XX new growth drivers that Merck repeatedly claim to have blockbuster potentials"
X Link @d_stock07734 2025-10-16T20:53Z XXX followers, XXX engagements
"$NWBO $RVMD is going to face competition from Incyte. INCB161734 (KRAS G12D) Preliminary Phase X Results Of INCB161734 A Novel Oral KRAS G12D Inhibitor In Patients With Advanced Or Metastatic Solid Tumors (Session Title: Proffered paper session: Developmental therapeutics. October XX 8:45 10:20 a.m. ET 2:45 4:20 p.m. CEST. Abstract #916O.)"
X Link @d_stock07734 2025-10-17T21:04Z XXX followers, 2089 engagements
"$NWBO It seems like Merck is going to file the approval of oral PCSK9 inhibitor (MK-0616) as the treatment for hypercholesterolemia. No doubt Merck knows that MK-0616 can be used for cancer treatment and it is among XX new growth drivers that have blockbuster potential. DoD (W81XWH-21-1-0532) once sponsored a trial on using Amgen's PCSK9 inhibitor (Evolocumab) in combination with BMS's two checking point inhibitors to treat lung cancer. Dr. Scott Antonia was the PI of the trial. Regeneron also sponsored a trial similar to the above one and the combination adopted in the trial is Regneron's"
X Link @d_stock07734 2025-10-09T04:43Z XXX followers, XXX engagements
"You guys still think about BO. Merck acquired Verona and Prometheus. The presentations can provide the hints on how Merck prices a BO target. Can Merck do the same for NWBO Take a closer look at the lead candidates from the two companies to see if they can be something complementary to or synergistic with DCVax. Ohtuvayre a dual PDE3 and PDE4 inhibitor from Verona can be used to overcome immunosuppression due to tumor-associated neutrophils. When DCs loaded with tumor-associated peptides migrate to lymph nodes they want to contact t-cells as many as possible. That's why IL-2 from Prometheus"
X Link @d_stock07734 2025-10-11T05:09Z XXX followers, XXX engagements
"A collaboration trial between Merck and TILT Biotherapeutics on ovarian cancer. One of the conclusions is that Median progression-free survival and overall survival were XX and XXX days respectively. Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a and 2) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. (PROTA) The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial"
X Link @d_stock07734 2025-10-13T05:17Z XXX followers, XXX engagements
"$NWBO ESMO 2025 preview Merck hopes for Daiichi redemption Did Merck strike the deal with Daiichi after Merck replaced BMS as the sponsor for the SPORE project Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition Conclusions This study reveals that timing may impact how ATL-DC and aPD1 combined therapies can alter the immune landscape of GBM and highlights tumor-associated macrophages as a major obstacle to clinical benefit"
X Link @d_stock07734 2025-10-17T21:13Z XXX followers, XXX engagements